Listed

Ocean Biomedical, Inc.

OCEAOTCCIK 1869974HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$958.0k, Q1 FY2025
Net income−$8.2m, Q1 FY2025
Ocean Biomedical, Inc., income statement, quarterly
Line itemUnitQ2 FY20222022-06-30Q3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31
Research and development$m3.2Research and development, Q2 FY2022, three months to 2022-06-30$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure1.9Research and development, Q3 FY2022, three months to 2022-09-30$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure0.2Research and development, Q4 FY2022, three months to 2022-12-31$161.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2024-11-25, accession 0001493152-24-047661. Derived: 12-month figure less the 9-month figure.Report this figure0.4Research and development, Q1 FY2023, three months to 2023-03-31$393.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure0.0Research and development, Q2 FY2023, three months to 2023-06-30$28.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure0.3Research and development, Q3 FY2023, three months to 2023-09-30$305.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure(0.0)Research and development, Q4 FY2023, three months to 2023-12-31−$17.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure0.0Research and development, Q1 FY2024, three months to 2024-03-31$26.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure0.0Research and development, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-12-23, accession 0001493152-24-051208. Derived: 6-month figure less the 3-month figure.Report this figure0.0Research and development, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-01-13, accession 0001493152-25-001880. Derived: 9-month figure less the 6-month figure.Report this figure0.0Research and development, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure0.0Research and development, Q1 FY2025, three months to 2025-03-31$18.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Operating income$m(6.9)Operating income, Q2 FY2022, three months to 2022-06-30−$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure(3.2)Operating income, Q3 FY2022, three months to 2022-09-30−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure(0.9)Operating income, Q4 FY2022, three months to 2022-12-31−$938.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-11-25, accession 0001493152-24-047661. Derived: 12-month figure less the 9-month figure.Report this figure(5.4)Operating income, Q1 FY2023, three months to 2023-03-31−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure(2.8)Operating income, Q2 FY2023, three months to 2023-06-30−$2.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(2.7)Operating income, Q3 FY2023, three months to 2023-09-30−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure0.7Operating income, Q4 FY2023, three months to 2023-12-31$660.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure(0.6)Operating income, Q1 FY2024, three months to 2024-03-31−$595.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(0.7)Operating income, Q2 FY2024, three months to 2024-06-30−$682.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(0.8)Operating income, Q3 FY2024, three months to 2024-09-30−$768.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure(1.8)Operating income, Q4 FY2024, three months to 2024-12-31−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure(1.0)Operating income, Q1 FY2025, three months to 2025-03-31−$958.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Interest expense$mnot reportednot reportednot reported0.0Interest expense, Q1 FY2023, three months to 2023-03-31$18.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure0.0Interest expense, Q2 FY2023, three months to 2023-06-30$24.0k. XBRL concept us-gaap:InterestExpense. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure0.0Interest expense, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure0.0Interest expense, Q4 FY2023, three months to 2023-12-31$13.1k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-11-25, accession 0001493152-24-047661. Derived: 12-month figure less the 9-month figure.Report this figure0.6Interest expense, Q1 FY2024, three months to 2024-03-31$637.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figurenot reportednot reportednot reported0.3Interest expense, Q1 FY2025, three months to 2025-03-31$343.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Net income$m(7.3)Net income, Q2 FY2022, three months to 2022-06-30−$7.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure(3.7)Net income, Q3 FY2022, three months to 2022-09-30−$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure(1.0)Net income, Q4 FY2022, three months to 2022-12-31−$983.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-11-25, accession 0001493152-24-047661. Derived: 12-month figure less the 9-month figure.Report this figure(72.1)Net income, Q1 FY2023, three months to 2023-03-31−$72.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure(11.4)Net income, Q2 FY2023, three months to 2023-06-30−$11.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(14.1)Net income, Q3 FY2023, three months to 2023-09-30−$14.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure(16.9)Net income, Q4 FY2023, three months to 2023-12-31−$16.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure13.0Net income, Q1 FY2024, three months to 2024-03-31$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(17.2)Net income, Q2 FY2024, three months to 2024-06-30−$17.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(3.7)Net income, Q3 FY2024, three months to 2024-09-30−$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure(1.5)Net income, Q4 FY2024, three months to 2024-12-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure(8.2)Net income, Q1 FY2025, three months to 2025-03-31−$8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Diluted EPS$ per share(0.31)Diluted EPS, Q2 FY2022, three months to 2022-06-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure(0.16)Diluted EPS, Q3 FY2022, three months to 2022-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figurenot reported(2.90)Diluted EPS, Q1 FY2023, three months to 2023-03-31−$2.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure(0.43)Diluted EPS, Q2 FY2023, three months to 2023-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(0.53)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figurenot reported0.48Diluted EPS, Q1 FY2024, three months to 2024-03-31$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(0.63)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(0.13)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figurenot reported(0.09)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Basic EPS$ per share(0.31)Basic EPS, Q2 FY2022, three months to 2022-06-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure(0.16)Basic EPS, Q3 FY2022, three months to 2022-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figurenot reported(2.90)Basic EPS, Q1 FY2023, three months to 2023-03-31−$2.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure(0.43)Basic EPS, Q2 FY2023, three months to 2023-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(0.53)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figurenot reported0.48Basic EPS, Q1 FY2024, three months to 2024-03-31$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(0.63)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(0.13)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figurenot reported(0.09)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure

Balance sheet

Cash and equivalents$4.0k, Q2 FY2024
Shareholders' equity−$92.4m, Q1 FY2025
Ocean Biomedical, Inc., balance sheet, quarterly
Line itemUnitQ2 FY20222022-06-30Q3 FY20222022-09-30FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31
Cash and equivalents$m0.6Cash and equivalents, Q2 FY2022, at 2022-06-30$576.8k. XBRL concept us-gaap:Cash. 10-Q filed 2022-07-11, accession 0001493152-22-019014.Report this figure0.5Cash and equivalents, Q3 FY2022, at 2022-09-30$472.1k. XBRL concept us-gaap:Cash. 10-Q filed 2022-10-17, accession 0001493152-22-028552.Report this figure0.0Cash and equivalents, FY2022, at 2022-12-31$34.0k. XBRL concept us-gaap:Cash. 10-K filed 2024-11-25, accession 0001493152-24-047661.Report this figure0.3Cash and equivalents, Q1 FY2023, at 2023-03-31$306.0k. XBRL concept us-gaap:Cash. 10-Q/A filed 2024-04-15, accession 0001493152-24-014676.Report this figurenot reported0.0Cash and equivalents, Q3 FY2023, at 2023-09-30$31.0k. XBRL concept us-gaap:Cash. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure0.0Cash and equivalents, FY2023, at 2023-12-31$4.0k. XBRL concept us-gaap:Cash. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure0.0Cash and equivalents, Q1 FY2024, at 2024-03-31$19.0k. XBRL concept us-gaap:Cash. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure0.0Cash and equivalents, Q2 FY2024, at 2024-06-30$4.0k. XBRL concept us-gaap:Cash. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figurenot reportednot reportednot reported
Current assets$m0.7Current assets, Q2 FY2022, at 2022-06-30$745.2k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2022-07-11, accession 0001493152-22-019014.Report this figure0.6Current assets, Q3 FY2022, at 2022-09-30$599.6k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2022-10-17, accession 0001493152-22-028552.Report this figure1.8Current assets, FY2022, at 2022-12-31$1.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2024-11-25, accession 0001493152-24-047661.Report this figure0.3Current assets, Q1 FY2023, at 2023-03-31$306.0k. XBRL concept us-gaap:AssetsCurrent. 10-Q/A filed 2024-04-15, accession 0001493152-24-014676.Report this figure2.2Current assets, Q2 FY2023, at 2023-06-30$2.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure1.0Current assets, Q3 FY2023, at 2023-09-30$1.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure2.1Current assets, FY2023, at 2023-12-31$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure1.8Current assets, Q1 FY2024, at 2024-03-31$1.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure1.3Current assets, Q2 FY2024, at 2024-06-30$1.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure1.0Current assets, Q3 FY2024, at 2024-09-30$1.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure0.8Current assets, FY2024, at 2024-12-31$812.0k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure1.5Current assets, Q1 FY2025, at 2025-03-31$1.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Total assets$m109Total assets, Q2 FY2022, at 2022-06-30$108.6m. XBRL concept us-gaap:Assets. 10-Q filed 2022-07-11, accession 0001493152-22-019014.Report this figure109Total assets, Q3 FY2022, at 2022-09-30$109.1m. XBRL concept us-gaap:Assets. 10-Q filed 2022-10-17, accession 0001493152-22-028552.Report this figure1.8Total assets, FY2022, at 2022-12-31$1.8m. XBRL concept us-gaap:Assets. 10-K filed 2024-11-25, accession 0001493152-24-047661.Report this figure0.3Total assets, Q1 FY2023, at 2023-03-31$306.0k. XBRL concept us-gaap:Assets. 10-Q/A filed 2024-04-15, accession 0001493152-24-014676.Report this figure2.2Total assets, Q2 FY2023, at 2023-06-30$2.2m. XBRL concept us-gaap:Assets. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure1.0Total assets, Q3 FY2023, at 2023-09-30$1.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure5.5Total assets, FY2023, at 2023-12-31$5.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure2.9Total assets, Q1 FY2024, at 2024-03-31$2.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure1.9Total assets, Q2 FY2024, at 2024-06-30$1.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure1.1Total assets, Q3 FY2024, at 2024-09-30$1.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure0.9Total assets, FY2024, at 2024-12-31$902.0k. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure1.6Total assets, Q1 FY2025, at 2025-03-31$1.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Current liabilities$m0.5Current liabilities, Q2 FY2022, at 2022-06-30$506.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2022-07-11, accession 0001493152-22-019014.Report this figure2.1Current liabilities, Q3 FY2022, at 2022-09-30$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2022-10-17, accession 0001493152-22-028552.Report this figure12.7Current liabilities, FY2022, at 2022-12-31$12.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2024-11-25, accession 0001493152-24-047661.Report this figure23.7Current liabilities, Q1 FY2023, at 2023-03-31$23.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q/A filed 2024-04-15, accession 0001493152-24-014676.Report this figure29.8Current liabilities, Q2 FY2023, at 2023-06-30$29.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure30.9Current liabilities, Q3 FY2023, at 2023-09-30$30.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure30.0Current liabilities, FY2023, at 2023-12-31$30.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure30.1Current liabilities, Q1 FY2024, at 2024-03-31$30.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure30.7Current liabilities, Q2 FY2024, at 2024-06-30$30.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure31.8Current liabilities, Q3 FY2024, at 2024-09-30$31.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure33.9Current liabilities, FY2024, at 2024-12-31$33.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure26.6Current liabilities, Q1 FY2025, at 2025-03-31$26.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Total liabilities$m3.7Total liabilities, Q2 FY2022, at 2022-06-30$3.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2022-07-11, accession 0001493152-22-019014.Report this figure5.2Total liabilities, Q3 FY2022, at 2022-09-30$5.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2022-10-17, accession 0001493152-22-028552.Report this figure12.7Total liabilities, FY2022, at 2022-12-31$12.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2024-11-25, accession 0001493152-24-047661.Report this figure55.1Total liabilities, Q1 FY2023, at 2023-03-31$55.1m. XBRL concept us-gaap:Liabilities. 10-Q/A filed 2024-04-15, accession 0001493152-24-014676.Report this figure63.8Total liabilities, Q2 FY2023, at 2023-06-30$63.8m. XBRL concept us-gaap:Liabilities. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure76.3Total liabilities, Q3 FY2023, at 2023-09-30$76.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure96.3Total liabilities, FY2023, at 2023-12-31$96.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure78.7Total liabilities, Q1 FY2024, at 2024-03-31$78.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure94.6Total liabilities, Q2 FY2024, at 2024-06-30$94.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure97.4Total liabilities, Q3 FY2024, at 2024-09-30$97.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure98.5Total liabilities, FY2024, at 2024-12-31$98.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure94.0Total liabilities, Q1 FY2025, at 2025-03-31$94.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure
Short-term borrowings$mnot reportednot reported0.8Short-term borrowings, FY2022, at 2022-12-31$776.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figurenot reported11.9Short-term borrowings, Q2 FY2023, at 2023-06-30$11.9m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figurenot reported3.2Short-term borrowings, FY2023, at 2023-12-31$3.2m. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figurenot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(9.5)Shareholders' equity, Q2 FY2022, at 2022-06-30−$9.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure(9.8)Shareholders' equity, Q3 FY2022, at 2022-09-30−$9.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure(10.8)Shareholders' equity, FY2022, at 2022-12-31−$10.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure(54.8)Shareholders' equity, Q1 FY2023, at 2023-03-31−$54.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure(61.7)Shareholders' equity, Q2 FY2023, at 2023-06-30−$61.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure(75.2)Shareholders' equity, Q3 FY2023, at 2023-09-30−$75.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure(90.8)Shareholders' equity, FY2023, at 2023-12-31−$90.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(75.8)Shareholders' equity, Q1 FY2024, at 2024-03-31−$75.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(92.7)Shareholders' equity, Q2 FY2024, at 2024-06-30−$92.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure(96.3)Shareholders' equity, Q3 FY2024, at 2024-09-30−$96.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-04-08, accession 0001641172-25-003155.Report this figure(97.6)Shareholders' equity, FY2024, at 2024-12-31−$97.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(92.4)Shareholders' equity, Q1 FY2025, at 2025-03-31−$92.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure

Cash flow

Operating cash flow−$356.0k, Q1 FY2025
Ocean Biomedical, Inc., cash flow, quarterly
Line itemUnitQ2 FY20222022-06-30Q3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31
Operating cash flow$k(151)Operating cash flow, Q2 FY2022, three months to 2022-06-30−$151.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678. Derived: 6-month figure less the 3-month figure.Report this figure(442)Operating cash flow, Q3 FY2022, three months to 2022-09-30−$442.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-04-15, accession 0001493152-24-014679. Derived: 9-month figure less the 6-month figure.Report this figure(33.0)Operating cash flow, Q4 FY2022, three months to 2022-12-31−$33.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-11-25, accession 0001493152-24-047661. Derived: 12-month figure less the 9-month figure.Report this figure(2,651)Operating cash flow, Q1 FY2023, three months to 2023-03-31−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure(4,782)Operating cash flow, Q2 FY2023, three months to 2023-06-30−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-12-23, accession 0001493152-24-051208. Derived: 6-month figure less the 3-month figure.Report this figure(1,130)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-01-13, accession 0001493152-25-001880. Derived: 9-month figure less the 6-month figure.Report this figure(866)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$866.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure(485)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$485.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure(290)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$290.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-12-23, accession 0001493152-24-051208. Derived: 6-month figure less the 3-month figure.Report this figure(957)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$957.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 9-month figure less the 6-month figure.Report this figure(2,448)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-04-08, accession 0001641172-25-003155. Derived: 12-month figure less the 9-month figure.Report this figure(356)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$356.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure

Shares

Diluted shares (weighted)91.02m, Q1 FY2025
Ocean Biomedical, Inc., shares, quarterly
Line itemUnitQ1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31
Diluted shares (weighted)m shares23.4Diluted shares (weighted), Q1 FY2022, three months to 2022-03-3123,355,432 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q/A filed 2024-04-15, accession 0001493152-24-014676.Report this figure23.4Diluted shares (weighted), Q2 FY2022, three months to 2022-06-3023,355,432 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q/A filed 2024-04-15, accession 0001493152-24-014678.Report this figure23.4Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3023,355,432 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-04-15, accession 0001493152-24-014679.Report this figure24.8Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3124,822,033 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-12-23, accession 0001493152-24-051207.Report this figure26.5Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3026,469,619 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure26.6Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3026,605,147 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure27.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3127,344,486 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure27.5Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3027,487,283 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-12-23, accession 0001493152-24-051208.Report this figure27.5Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3027,487,283 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-01-13, accession 0001493152-25-001880.Report this figure91.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3191,024,268 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure

Shares outstanding: 232.37mShares outstanding, period not labelled, at 2025-05-15232,365,143 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2025-05-15, accession 0001641172-25-011080.Report this figure at May 15, 2025, from the cover of the 10-Q filed May 15, 2025.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.